Andrew Kenneth Takle

This inventor holds 18 USPTO granted patents and 1 published patent application and 1 EPO patent, primarily in Antibacterial Compounds. Top assignees: Smithkline Beecham Corporation, Glaxo Group Limited. Active years: 2000-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Kenneth Takle. Retrieved from https://idiyas.com/inventor/andrew-kenneth-takle

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 1)

% Patents Active = 22.2

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.5

ph-index = 7

Forward Citations = 128(Granted Patents)

Location History:

Great Dunmow, GB (2000 - 2007)
Harlow, GB (2003 - 2011)

Company Filing History:

15 out of 2,198

Smithkline Beecham Corporation

Years Active: 2000-2011

Loading Chart...

Areas of Expertise:

Antibacterial Compounds

Raf Kinase Inhibitors

Estrogen Receptor Beta

Indazoles

Pyridine Derivatives

Piperazine Derivatives

Nitrogen-Containing Heterocycles

Quinoline Derivatives

Pleuromutilin Derivatives

Imidazole Derivatives

Pyridylfurans

Carbamoyloxy Derivatives

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7960563 - Indazoles used to treat estrogen receptor beta mediated disorders (2011-06-14),

2. 7956083 - Compounds (2011-06-07),

3. 7452906 - Pyridine derivatives as Raf kinase inhibitors (2008-11-18),

4. 7446106 - Pyridylfurans and pyrroles as Raf kinase inhibitors (2008-11-04),

5. 7381728 - Piperazine derivatives useful for the treatment of gastrointestinal disorders (2008-06-03),

6. 7375105 - Pyridine substituted furan derivatives as Raf kinase inhibitors (2008-05-20),

7. 7297694 - Pyridylfurans and pyrroles as Raf kinase inhibitors (2007-11-20),

8. 7297693 - Nitrogen-containing heterocyclic compounds and their use as Raf inhibitors (2007-11-20),

9. 7282500 - Imidazole-2-carboxamide derivatives as Raf kinase inhibitors (2007-10-16),

10. 7235658 - Imidazol derivatives as Raf kinase inhibitors (2007-06-26),

11. 7199137 - Imidazole derivatives as Raf kinase inhibitors (2007-04-03),

12. 7045524 - Pleuromutilin derivatives with antimicrobial activity (2006-05-16),

13. 7026336 - Compounds (2006-04-11),

14. 6987119 - Imidazol-2-carboxamide derivatives as raf kinase inhibitors (2006-01-17),

15. 6911442 - Quinoline derivatives as antibacterials (2005-06-28),

Title: The Innovative Contributions of Andrew Kenneth Takle

Introduction

Andrew Kenneth Takle is a notable inventor based in Harlow, GB. He has made significant contributions to the field of pharmacology, particularly in the development of novel compounds for treating estrogen receptor beta mediated disorders. With a total of 18 patents to his name, Takle's work has had a considerable impact on medical research and treatment options.

Latest Patents

Among his latest patents, Takle has developed indazole derivatives that exhibit pharmacological activity. These compounds are designed for the treatment of estrogen receptor beta mediated diseases. Additionally, he has created novel indole derivatives with similar pharmacological properties, further expanding the potential for therapeutic applications in this area.

Career Highlights

Throughout his career, Takle has worked with prominent companies in the pharmaceutical industry, including SmithKline Beecham Corporation and Glaxo Group Limited. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in drug development.

Collaborations

Takle has collaborated with several professionals in his field, including David Kenneth Dean and David Matthew Wilson. These partnerships have facilitated the exchange of ideas and fostered innovation in their shared research endeavors.

Conclusion

Andrew Kenneth Takle's contributions to pharmacology and his innovative patents highlight his role as a significant figure in medical research. His work continues to influence the development of treatments for critical health issues.

Profile summary based on public USPTO records.